Hemab Therapeutics Holdings

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Cambridge, Massachusetts and currently employs 72 full-time employees. The company went IPO on 2026-05-01. The firm is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. The company is also advancing multiple preclinical and discovery-stage assets.